(Total Views: 752)
Posted On: 01/25/2022 9:07:56 PM
Post# of 154140
Actually, I'm not shocked.
The time has come, the Walrus said, to talk of many things.
But mostly that we have more data, but less money - and debts to pay - and a weak stock to generate cash. And the last CFO couldn't even keep a convincing set of financial controls in place.
A name CEO might bring money with him. Otherwise, time for a partner to move this molecule forward. Time to wall-off any perceived liabilities and be cleaner-than-clean with a regulator for Board chair.
My guess is that NP understands this, and that his earn-out - and leronlimab's benefit to humanity - may be higher if he takes himself out of the conversation.
We've always said we are in it for the science. We're going to find out what others - others with money and scientists working for them - think of that.
The time has come, the Walrus said, to talk of many things.
But mostly that we have more data, but less money - and debts to pay - and a weak stock to generate cash. And the last CFO couldn't even keep a convincing set of financial controls in place.
A name CEO might bring money with him. Otherwise, time for a partner to move this molecule forward. Time to wall-off any perceived liabilities and be cleaner-than-clean with a regulator for Board chair.
My guess is that NP understands this, and that his earn-out - and leronlimab's benefit to humanity - may be higher if he takes himself out of the conversation.
We've always said we are in it for the science. We're going to find out what others - others with money and scientists working for them - think of that.
(10)
(0)
